Percutaneous “edge-to-edge” leaflet repair in patients with secondary mitral valve regurgitation

Abstract

Functional or secondary mitral regurgitation (MR) is a heterogeneous entity afflicting patients with heart failure both with reduced or preserved left ventricular ejection fraction. It results from an imbalance between closing forces and tethering or pushing strengths acting on the valve in the absence of structural alterations of mitral valve (MV) apparatus. According to previous studies, more than 20% of patients with heart failure and reduced left ventricular ejection fraction have severe MR, even though the definition of the severity of the MV disease in this setting remains a debated issue due to the poor reproducibility of quantitative measurements and its dynamic nature, highly dependent on left ventricular loading conditions and performance in relation to optimization of medical treatment. Furthermore, it is still unclear whether MR is a direct contributor to a worse prognosis or merely a marker of severity of the disease affecting the left ventricle. Isolated MV surgery in these patients is burdened by significant operative mortality, high rates of recurrent MR and absence of proven survival benefit. In recent years, percutaneous treatment of functional MR arose as a viable and safe alternative to conventional surgery, proving capable of reducing symptoms and recurrent hospitalization rates for heart failure, and even improving prognosis in selected patients. In this review we will discuss the percutaneous treatment of functional MR through transcatheter “edge-to-edge” leaflet repair performed with the two systems currently available: the MitraClip System and the PASCAL Repair System, from available evidence to technical practice.

Keywords

Functional mitral valve disease / mitral regurgitation / mitral insufficiency / heart failure / MitraClip / PASCAL

References

[1] Baumgartner H,Bax JJ,Hamm C.2017 ESC/EACTS Guidelines for the management of valvular heart disease..Eur Heart J2017;38:2739-91

[2] Ennezat PV,Pibarot P.Secondary mitral regurgitation in heart failure with reduced or preserved left ventricular ejection fraction..Cardiology2013;125:110-7

[3] Inciardi RM,Benfari G.Fill in the gaps of secondary mitral regurgitation: a continuum challenge from pathophysiology to prognosis..Curr Heart Fail Rep2018;15:106-15

[4] Iung B.Fattouch K,Angelini GD.Prevalence and definition of secondary mitral regurgitation..Secondary Mitral Valve Regurgitation.2015;LondonSpringer1-6

[5] Rossi A,Faggiano P,Cicoira M.Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy..Heart2011;97:1675-80

[6] Grigioni F,Zehr KJ,Tajik AJ.Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment..Circulation2001;103:1759-64

[7] Lancellotti P,Toussaint AC.Prognostic importance of exercise-induced changes in mitral regurgitation in patients with chronic ischemic left ventricular dysfunction..Circulation2003;108:1713-7

[8] Lancellotti P,Hagendorff A,Edvardsen T.Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging..Eur Heart J Cardiovasc Imaging2013;14:611-44

[9] Nishimura RA,Bonow RO,Erwin JP3rd.2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines..J Am Coll Cardiol2017;70:252-89

[10] Patel JB,Barnes ME,Daly RC.Mitral regurgitation in patients with advanced systolic heart failure..J Card Fail2004;10:285-91

[11] Grayburn PA,DeMaria AN,Lowes B.Echocardiographic predictors of morbidity and mortality in patients with advanced heart failure: the Beta-blocker Evaluation of Survival Trial (BEST)..J Am Coll Cardiol2005;45:1064-71

[12] Grayburn PA,Hung J,Liang D.Defining “severe” secondary mitral regurgitation: emphasizing an integrated approach..J Am Coll Cardiol2014;64:2792-801

[13] Feldman T,Elmariah S,Trento A.Randomized comparison of percutaneous repair and surgery for mitral regurgitation: 5-year results of EVEREST II..J Am Coll Cardiol2015;66:2844-54

[14] Obadia JF,Leurent G,Bonnet G.Percutaneous repair or medical treatment for secondary mitral regurgitation..N Engl J Med2018;379:2297-306

[15] Stone GW,Abraham WT,Lim DS.Transcatheter mitral-valve repair in patients with heart failure..N Engl J Med2018;379:2307-18

[16] Feldman T,Glower DD,Rinaldi MJ.Percutaneous repair or surgery for mitral regurgitation..N Engl J Med2011;364:1395-406

[17] Capodanno D.Antithrombotic strategies in valvular and structural heart disease interventions: current status and future directions..Interv Cardiol Clin2013;2:635-42

[18] Geis N,Kiriakou C,Frankenstein L.Temporary oral anticoagulation after MitraClip - a strategy to lower the incidence of post-procedural stroke?.Acta Cardiol2020;75:61-7

[19] Seeger J,Kessler M,Wöhrle J.Apixaban after percutaneous Edge-to-Edge mitral valve repair in patients with maintained sinus rhythm..JACC Cardiovasc Interv2019;12:214-6

[20] Maisano F,Baldus S,Hausleiter J.Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe..J Am Coll Cardiol2013;62:1052-61

[21] Nickenig G,Franzen O,Vanderheyden M.Percutaneous mitral valve edge-to-edge repair: in-hospital results and 1-year follow-up of 628 patients of the 2011-2012 Pilot European Sentinel Registry..J Am Coll Cardiol2014;64:875-84

[22] Grayburn PA,Packer M.Proportionate and disproportionate functional mitral regurgitation: a new conceptual framework that reconciles the results of the MITRA-FR and COAPT trials..JACC Cardiovasc Imaging2019;12:353-62

[23] Lim DS,Spargias K,O’Neill WW.Transcatheter valve repair for patients with mitral regurgitation: 30-day results of the CLASP study..JACC Cardiovasc Interv2019;12:1369-78

[24] Mazimba S,Kipperman R,Kar S.Six-month outcomes from the multicenter, prospective study with the novel PASCAL Transcatheter Valve Repair System for Patients with Mitral Regurgitation in the CLASP Study..J Card Fail2019;25:S6

[25] Kar S,Lim S,Webb J.TCT-91 1-year outcomes from the multicenter, prospective study with the novel PASCAL transcatheter valve repair system for patients with mitral regurgitation in the CLASP study..J Am Coll Cardiol2019;74:B91

[26] Packer M.New evidence supporting a novel conceptual framework for distinguishing proportionate and disproportionate functional mitral regurgitation..JAMA Cardiol2020;469